The trial in Japan has two patient groups, one with 30 pneumonia-induced ARDS subjects including treatment and registry groups, and the other with five COVID-induced ARDS subjects.
Both groups reported favorable topline results, including meeting the primary endpoint of ventilator-free days and the secondary endpoint of 90-day mortality. The data were in line with the results from Athersys's placebo-controlled study conducted in the US and UK.
MultiStem cell therapy has orphan regenerative medicine product designation in Japan for use in the treatment of ARDS.
Shares of Athersys were up 2.6% in afternoon trading.
Price: 1.58, Change: +0.04, Percent Change: +2.60
|Research Alert: CFRA Keeps Buy Opinion On Shares Of ...|
|Technology & Telecommunication Acquisition Prices IPO|
|US Stocks End Week Mixed on Second Weekly Decline Am...|
|Industrial Tech Acquisitions II Closes IPO|
|Churchill Downs Makes Online Gaming President's Job ...|